GenAssist Announces FDA Approval of New Drug Application for GEN6050X Exon 50 Skipping Therapy On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has received clearance from the U.S Food and Drug Administration(FDA) for its Investigational New Drug (IND) application for GEN6050X, a first-in-class base editing drug for Duchenne Muscular Dystrophy (DMD). GenAssist is planning to conduct clinical study globally for GEN6050X.

GenAssist Announces FDA Approval of New Drug Application for GEN6050X Exon 50 Skipping Therapy

👉 Read More: dmdwarrior.com

#dmd #duchenne #GenAssist #GEN6050X #exon50 #exon50skipping

GenAssist Ltd Achieves FDA Clearance for Innovative Base Editing Treatment for Duchenne Muscular Dystrophy GenAssist Ltd proudly announces FDA approval for its groundbreaking base editing drug GEN6050X, aimed at treating Duchenne Muscular Dystrophy, marking a significant advancement in gene therapy.

GenAssist Ltd Achieves FDA Clearance for Innovative Base Editing Treatment for Duchenne Muscular Dystrophy #China #Suzhou #Duchenne_Muscular_Dystrophy #GenAssist_Ltd #GEN6050X